If your company is developing diagnostics, therapeutics, vaccines, or other products (software, wearable devices, etc.) to address the SARS-CoV2 pandemic, then this is the webinar for you!
Update: October 2020- Check the current EZ BAA for the most up to date information on Areas of Interest.
The Office of Biomedical Advanced Research and Development Authority (BARDA) is working to identify and fund medical countermeasures to address the SARS-CoV2 pandemic. Life Science Washington Institute is one of 13 BARDA DRIVe Accelerators to assist companies in connecting with BARDA funding resources. Life Science WA Institute hosted this interactive webinar in collaboration with officials from BARDA DRIVe team. BARDA officials delivered a reverse pitch about areas of interest. Additionally, 98point6, a DRIVe-funded company, spoke about their pathway to funding and how COVID-19 has impacted their business.
- EZ BAA Area of Interest 4.3: Vaccines- Tanima Sinha, MSc, MScPh, Lead Interdisciplinary Scientist (Project Officer) at Department of Health and Human Services
- EZ BAA Area of Interest 4.1D: Patient Monitoring and Diagnostic Tools, Rapidly Deployable Capabilities- Kim Sciarretta, Ph.D., Interdisciplinary Scientist/Project Officer Biomedical Advanced Research and Development Authority (BARDA), HHS
- NIH RADx Initiative- Kerrie Gruber-DeMarco, Ph.D., Intergovernmental & Commercial Partnership Lead, Biomedical Advanced Research & Development Authority interagency partnership builder
- EZ BAA Area of Interest 4.1D: Wearable devices and aspects of their development- Šeila Selimović, Ph.D., Program Manager, Early Notification to Act, Control and Treat (ENACT)
- 98point6: Pathway to DRIVe-funding – Dr. David McCune, Medical Director of Clinical Research and Population Health
Links referenced in the webinar:
- The goal of the Point Of Care Technology Research Network is to develop technologies with clinical applications using a network model that enhances complementary strengths and builds multidisciplinary partnerships.
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American. (RADx overview and application link)
- NIH NCI Serological Sciences Network for COVID-19 (SeroNet) The network is being developed in close collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and other parts of NIH and the Department of Health and Human Services.